Literature DB >> 26622740

Three-way complex variant translocation involving short arm chromosome (1;9;22)(p36;q34;q11) in a chronic myeloid leukemia patient.

Muhammad Asif1, Abrar Hussain1, Arif Malik2, Mahmood Rasool3.   

Abstract

Chronic myeloid leukemia (CML) is a disease of the clonal hematopoietic stem cells caused by a balanced translocation between the long arms of chromosomes 9 and 22. Overall, 90-95% of CML patients present with a Philadelphia (Ph) chromosome t(9;22)(q34;q11) translocation and in addition, variant complex translocations, involving a third chromosome, are observed in 5-8% of CML patients. Cytogenic testing using bone marrow sample was performed and the FISH test was used for the detection of BCR-ABL fusion gene and complete blood analysis of CML patient was also performed. Results of hematological analysis showed the induced values of white blood cells (168,5000/mm3) and platelets (300,000/mm3) and FISH analysis test showed that 98% cells were positive for BCR/ABL gene translocation. The present study describes a three-way (1;9;22)(p36;q34;q11) Ph chromosome translocation in a 24-year-old female with CML. The patient, who was in the chronic phase of the disease, was treated with daily dose of 400 mg/dl with imatinib mesylateand was monitored constantly at various intervals over a 6-month period. Many studies reported that certain CML patents with variant translocation responded poorly to imatinib. In the current case report, the CML patient exhibited a suboptimal response to imatinib, denoting a poor prognosis.

Entities:  

Keywords:  chronic myeloid leukemia; imatinib; variant translocation

Year:  2015        PMID: 26622740      PMCID: PMC4533745          DOI: 10.3892/ol.2015.3495

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  15 in total

Review 1.  The biology of chronic myeloid leukemia.

Authors:  S Faderl; M Talpaz; Z Estrov; S O'Brien; R Kurzrock; H M Kantarjian
Journal:  N Engl J Med       Date:  1999-07-15       Impact factor: 91.245

Review 2.  Tyrosine kinase inhibitors in chronic myeloid leukemia.

Authors:  C L Sawyers; B Druker
Journal:  Cancer J Sci Am       Date:  1999 Mar-Apr

Review 3.  Nomenclature evolution: Changes in the ISCN from the 2005 to the 2009 edition.

Authors:  A R Brothman; D L Persons; L G Shaffer
Journal:  Cytogenet Genome Res       Date:  2010-01-29       Impact factor: 1.636

4.  U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid.

Authors:  Martin H Cohen; Ramzi Dagher; Donna J Griebel; Amna Ibrahim; Alison Martin; Nancy S Scher; Gerald H Sokol; Grant A Williams; Richard Pazdur
Journal:  Oncologist       Date:  2002

5.  Complex chromosome rearrangements may locate the bcr/abl fusion gene sites other than 22q11.

Authors:  M Sessarego; G Fugazza; R Bruzzone; A Ballestrero; M Miglino; A Bacigalupo
Journal:  Haematologica       Date:  2000-01       Impact factor: 9.941

Review 6.  Chronic myeloid leukemia: diagnosis and treatment.

Authors:  Alfonso Quintás-Cardama; Jorge E Cortes
Journal:  Mayo Clin Proc       Date:  2006-07       Impact factor: 7.616

7.  Novel complex t(V;9;22) rearrangements in three cases with chronic myeloid leukemia and a rare translocation in a case with classical Philadelphia chromosome.

Authors:  Hasmik Mkrtchyan; Seda Ghazaryan; Gayane Avetisyan; Anna Hovhannisyan; Laura Muradyan; Smbat Daghbashyan; Constanze Karst; Madeleine Gross; Sophie Hinreiner; Rouben Aroutiounian; Thomas Liehr
Journal:  Oncol Rep       Date:  2008-07       Impact factor: 3.906

8.  Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia.

Authors:  Deborah White; Verity Saunders; Andrew Grigg; Chris Arthur; Robin Filshie; Michael F Leahy; Kevin Lynch; L Bik To; Timothy Hughes
Journal:  J Clin Oncol       Date:  2007-10-01       Impact factor: 44.544

9.  Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia.

Authors:  Sandra W Cowan-Jacob; Gabriele Fendrich; Andreas Floersheimer; Pascal Furet; Janis Liebetanz; Gabriele Rummel; Paul Rheinberger; Mario Centeleghe; Doriano Fabbro; Paul W Manley
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2006-12-13

10.  Three-way Philadelphia translocation t(9;10;22)(q34;p11.2;q11.2) as a secondary abnormality in an imatinib mesylate-resistant chronic myeloid leukemia patient.

Authors:  Walid Al-Achkar; Abdulsamad Wafa; Adnan Ikhtiar; Thomas Liehr
Journal:  Oncol Lett       Date:  2013-03-05       Impact factor: 2.967

View more
  2 in total

1.  A novel three-way Philadelphia Variant t(9;22;17)(q34;q11.2;q12) in chronic myeloid leukemia: A case report.

Authors:  Kathy Allen-Proctor; Elizabeth Ruckdeschel; Rana Naous
Journal:  Mol Clin Oncol       Date:  2017-12-08

2.  Simultaneous involvement of 11q23 translocation resulting in chimeric MLL-AFF1 and a second translocation [t (9;21) (p13; p11.2)] in an infant acute lymphoblastic leukemia patient at relapse: A case report.

Authors:  Guangming Liu; Xianglan Lu; Young Mi Kim; Xianfu Wang; Shibo Li; Yuanyuan Liu
Journal:  Medicine (Baltimore)       Date:  2018-05       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.